Furthermore, the dynamics of Erk1R84H activity in the course of oncogenesis, i.e., its strong downregulation, suggests that also in those cases of Ras-, Raf-, or MEK-driven cancer, where Erk activity is not readily detectable, Erk may be an important driver of the malignancy. The gene discussed is MAP2K7; the disease is cancer.